





SCHÖFFMANN

Angela



Discovery of more potent GABA_A ligands, Investigation of derivatives on vanilloid receptor-1, Elucidation of SAR and pharmacophore modell, Development of new scaffold for antiepileptic drugs.

What are you doing now?

From a professional perspective: Country Safety Lead, sanofi-aventis GmbH, Vienna, Austria.

From a personal perspective: Enjoying maternity leave and taking care of a lovely not-yet-a-year-old baby boy.

What was the impact of the MolTag program on your further career?

I significantly improved my (scientific) English and greatly benefited from experience in project management, from great team work and international collaboration with top scientists.

Did you keep connections with some former colleagues?

Yes.

What did you particularly like about the MolTag program?

The spirit - motivated, open-minded, skilled and open-hearted people working together

What is your recommendation for current MolTag PhD students?

Enjoy a great time together and make use of any occasion to take a glance into your peer's field of work. Travel. Stay in touch.

Finishing year: 2015

Supervisor: Steffen Hering, Faculty of Life Sciences, University of Vienna

Thesis title: Natural Products as Scaffold for the Development of GABA_A Receptor Ligands.

Current Position and Employer: Country Safety Lead, sanofi-aventis GmbH, Vienna, Austria

MolTag alumni page:

Angela Schöffmann (univie.ac.at)



